We are live on
!
Find out more
ATI
Act Two Investors Portfolio holdings
AUM
$453M
1-Year Est. Return
10.9%
This Fund
S&P 500
This Quarter
Est. Return
+12.51%
1 Year Est. Return
+10.9%
3 Year Est. Return
+52.85%
5 Year Est. Return
+67.7%
10 Year Est. Return
–
AUM
$463M
AUM Growth
+$89.2M
(+24%)
Cap. Flow
+$41.9M
Cap. Flow
% of AUM
9.05%
Top 10 Holdings %
Top 10 Hldgs %
68.86%
Holding
50
New
14
Increased
28
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$8.51M |
| 2 |
Enbridge
ENB
|
+$7.25M |
| 3 |
Visa
V
|
+$5.92M |
| 4 |
Vanguard Total Bond Market
BND
|
+$4.18M |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$3.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$10.3M |
| 2 |
GE HealthCare
GEHC
|
+$823K |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$750K |
| 4 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$730K |
| 5 |
PayPal
PYPL
|
+$228K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.04% |
| 2 | Communication Services | 19.34% |
| 3 | Financials | 12.92% |
| 4 | Healthcare | 10.66% |
| 5 | Consumer Discretionary | 6.83% |
Similar funds
FNB
VV
CFG
AA
MCM
TPWM
GSIAS
HIM
Act Two Investors's Q4 2023 Portfolio in Review
As of Q4 2023, Act Two Investors held 50 positions worth $463M, up 24% from $374M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Act Two Investors deployed $41.9M of net new capital in Q4 2023, opening 14 new positions and adding to 28 existing holdings. Its largest new stake was Johnson & Johnson: 11,790 shares worth $1.85M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 24% a quarter earlier, followed by Communication Services and Financials.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $10.3M trimmed.
- Act Two Investors's largest Q4 2023 buy was Johnson & Johnson: 11,790 shares worth $1.85M.
- Act Two Investors added most to Verizon in Q4 2023, an estimated $8.51M increase.
- Act Two Investors's biggest Q4 2023 reduction was Thermo Fisher Scientific, cutting an estimated $10.3M.
- Act Two Investors fully exited State Street Health Care Select Sector SPDR ETF in Q4 2023, selling an estimated $750K.
- Act Two Investors's ten largest holdings make up 69% of its $463M portfolio in Q4 2023.
- Act Two Investors opened 14 new positions and closed 3 in Q4 2023.
- Act Two Investors's portfolio value rose 24% quarter-over-quarter to $463M.
Based on Act Two Investors's 13F filing for Q4 2023, filed 12 Feb 2024.